Tag Archives: Disease Progression

Exploring Lived Space as Experienced by Persons With Dementia (BMC Geriatrics)

Posted on July 16, 2018 by Dementia and Elderly Care News

Summary A systematic meta-synthesis concerning the broad topic of the experience(s) of space (whether physical, social or existential) on the part of persons living with dementia has identified four domains in the experience of “lived space”: (i) belonging (ii) meaningfulness … Continue reading →

Progression of Neurological Diseases Presaged By Hidden Alterations in Artistic Style? (BBC News / Neuropsychology)

Posted on December 29, 2016 by Dementia and Elderly Care News

Summary Psychological researchers performed detailed mathematical analysis (“fractal analysis”) of barely perceptible changes to the brushstrokes used by artists, some of whom later developed neurological diseases. Analysis of hidden patterns of change in the fractal dimension of paintings reveals that … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest | Tagged Alterations to Artistic Style, and Wear Valleys NHS Trust, Artworks, BBC Health News, Department of Computer Science: Maynooth University, Department of Psychology: University of Liverpool, Disease Progression, Fine Art, Fine Motor Control, Fractal Analysis of Artistic Brushstrokes, Fractal Analysis of Neurological Changes (In Artists), Fractal Analysis of Paintings, Ireland, Maynooth University, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuropsychology (Journal), Progression of Neurological Diseases, Pyschology of Art, Symptoms and Progression of Dementia, Tees Esk, University of Liverpool, Variations in Motor Control | Leave a comment

World Alzheimer’s Day (BBC News / ARUK / OHE / NHS Choices)

Posted on September 22, 2015 by Dementia and Elderly Care News

Summary To mark World Alzheimer’s Day, life-expectancy and dementia incidence statistics, commissioned from the Office of Health Economics, have been used to arrive at the projection that perhaps one in three people born in the UK this year could develop … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Commissioning, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Management of Condition, Models of Dementia Care, NHS Digital (Previously NHS Choices), Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Ageing Population, Ageing Society, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Behind the Headlines, CFAS I Study, Cognitive Functioning and Ageing Study (CFAS), Costs of Dementia in UK, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Dementia Innovation, Dementia Research, Dementia Research Champions Group, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Epidemiology, Estimation of Future Cases of Dementia: From Males / Females Born in 2015, Forecasting Life Expectancy, Gender (Sex), Gender Differences in Diagnosis Rates, Incidence Studies, Life Expectancy, Life Table Data, Life Tables, National Life Tables, Office of Health Economics (OHE), OHE Consulting, OHE: Office of Health Economics, Prevalence, Prevalence of Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Trajectory of Dementia in the UK | Leave a comment

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Posted on July 22, 2015 by Dementia and Elderly Care News

Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Association International Conference (Washington, Alzheimer’s Association International Conference® (AAIC®) 2015, Alzheimer’s Research UK (ARUK), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, ARUK: Alzheimer’s Research UK, BBC Health News, Big Pharma, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Eli Lilly, EXPEDITION Studies, β-amyloid, July 2015), Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody | Leave a comment

Defeat Dementia Report (Alzheimer’s Research UK / OHE / BBC News)

Posted on June 23, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK (ARUK) released their “Defeat Dementia: the evidence and a vision for action” last week to coincide with the Global Dementia Legacy Event and the launch of their “Defeat Dementia” campaign. This report draws on analyses from … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Age of Dementia Onset, Alzheimer’s Disease: Prevalence, ARUK: Alzheimer’s Research UK, BBC Health News, Burden of Alzheimer’s Disease, Burden of Dementia, Burden on Caregivers, Carer Burden in Dementia, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Economic Analyses, Economic Case for Prevention, Economic Modelling, Epidemiology, Epidemiology and Statistics, Family Carers, Global Dementia Legacy Event, Informal Carers, Institute for Public Policy Research (ippr), ippr: Institute for Public Policy Research, Office of Health Economics (OHE), Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Social Epidemiology, University College London, Unpaid Caregivers (Carers), Unpaid Carers, Wider Societal Burden | Leave a comment

Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)

Posted on March 2, 2014 by Dementia and Elderly Care News

Summary Accurate and sensitive tools are required for the early detection / diagnosis of Alzheimer’s Disease, particularly to assist research. Alzheimer’s Disease clinical trials make increasing use of biomarkers, particularly neuroimaging markers and cerebrospinal fluid (CSF) biomarkers obtained via invasive … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Quick Insights | Tagged Aβ42, Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort, Alzheimer’s Disease Clinical Trials, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Argentina, Australia, Autonomous Systems Laboratory: Universidad Politécnica de Madrid, Avid’s AV-45 (Florbetapir), Belgium, Beta-Amyloid, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomedical Engineering Laboratory: Okayama University, BM List of AD Biomarkers, BM=(w o τ aβ hc fc tac), Canada, Cerebrospinal Fluid (CSF), Chile, Clearance of Amyloid Beta Protein, Compliance with Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Computed Tomography (CT), CSF, CSF Aβ, CSF Aβ(1-42), CSF Tau, Default-Mode Network (DMN), Dementia Research, Denmark, Disease Progression, Finland, Fludeoxyglucose FDG PET, Flutemetamol (18F), fMRI, France, Frontiers in Aging Neuroscience, Functional Connectivity, Functional Magnetic Resonance Imaging (fMRI), GE’s Flutametamol, Germany, Global Alzheimer’s Association Interactive Network (GAAIN), Hippocampus, Hyperphosphorylated Tau, India, Israel, Italy, β-amyloid, β-Amyloid 1-42 (Aβ42), Japan, Lumbar Puncture Compliance, Lumbar Punctures, Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Measurement of Treatment Effects, Mexico, Morphometric Analysis, Network-Based Biomarkers, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, o (Orientation), Okayama University, Poland, Positron Emission Tomography (PET), Quintiles, Resting-State fMRI (R-fMRI), South Africa, Spain, Sweden, Tactile Biomarker (tac), Taiwan, Tau Pathology, Tau Protein, Universidad Politécnica de Madrid, USA, Volumetric MRI, w (Word Recognition) | Leave a comment

Tag Archives: Disease Progression

Progression of Neurological Diseases Presaged By Hidden Alterations in Artistic Style? (BBC News / Neuropsychology)

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites